Literature DB >> 25946589

[Cost of breast cancer treatment by clinical stage in the Basque Country, Spain].

Arantzazu Arrospide, Myriam Soto-Gordoa, Teresa Acaiturri, Guillermo López-Vivanco, Luis Carlos Abecia, Javier Mar.   

Abstract

BACKGROUND: The burden of breast cancer is important for the healthcare system. In the context of the evaluation of the breast cancer screening program in the Basque Country it is important to determine the unitary costs related to diagnosis as well as the treatment costs depending on the clinical stage at detection. The main objective was to calculate the total cost and the components of breast cancer (BC) treatment depending on the clinical stage by 2011.
METHODS: The estimated costs include BC diagnosis as so as to initial treatment and follow-up, based on resource consumption and unitary costs of the Basque Health Services. Micro-costing technique was applied based on the clinical guidelines.
RESULTS: Our model showed the estimated loss of productivity due to premature The initial cost was 9.838€ for the stage 0, 17.273€ for stage I, 22.145€ for stage II and 28.776€ for stage III. The follow up annual cost was 172€ for the stage 0, 908€ for stage I, 994€ for stage II and 1.166€ for stage III. The annual cost for stage IV was 17879€.
CONCLUSIONS: Chemotherapy determines the greatest percentage of BC costs. The two main drivers of the total cost of breast cancer are the initial treatment of stages I to III and the cost of stage IV, the latter reaching € 50,061 per patient.

Entities:  

Mesh:

Year:  2015        PMID: 25946589     DOI: 10.4321/S1135-57272015000100010

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  4 in total

1.  Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

Authors:  S Pérez Ramírez; M Del Monte-Millán; S López-Tarruella; N Martínez Jáñez; I Márquez-Rodas; F Lobo Samper; Y Izarzugaza Perón; C Rubio Terres; D Rubio Rodríguez; J Á García-Sáenz; F Moreno Antón; P Zamora Auñón; M Arroyo Yustos; M Á Lara Álvarez; E M Ciruelos Gil; L Manso Sánchez; M J Echarri González; J A Guerra Martínez; C Jara Sánchez; C Bueno Muiño; S García Adrián; J R Carrión Galindo; V Valentín Maganto; M Martín
Journal:  Clin Transl Oncol       Date:  2019-07-12       Impact factor: 3.405

2.  Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study.

Authors:  Concepción Pérez-Hernández; Antonio Javier Jiménez-López; Almudena Sanz-Yagüe; Javier Mar-Medina; Igor Larrañaga; Begoña Soler-López
Journal:  Pain Ther       Date:  2018-07-05

3.  Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.

Authors:  Arantzazu Arrospide; Montserrat Rue; Nicolien T van Ravesteyn; Merce Comas; Myriam Soto-Gordoa; Garbiñe Sarriugarte; Javier Mar
Journal:  BMC Cancer       Date:  2016-06-01       Impact factor: 4.430

4.  Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation.

Authors:  Arantzazu Arrospide; Montserrat Rue; Nicolien T van Ravesteyn; Merce Comas; Nerea Larrañaga; Garbiñe Sarriugarte; Javier Mar
Journal:  BMC Cancer       Date:  2015-10-12       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.